5 Firms Aid As Jazz Pays $7.2B For Rare Disease Drugmaker
By Benjamin Horney (February 3, 2021, 8:58 AM EST) -- Jazz Pharmaceuticals PLC has agreed to pay $7.2 billion to pick up GW Pharmaceuticals PLC, which develops cannabinoid-based treatments for rare diseases, the companies said Wednesday, in a deal cooked up by five law firms.
The agreement sees Ireland-based Jazz acquiring U.K.-headquartered GW, adding to the buyer's portfolio a pharmaceutical company focused on making cannabinoid-derived treatments for rare diseases like Lennox-Gastaut Syndrome, Dravet syndrome and tuberous sclerosis complex, according to a statement.
Jazz is represented by Wachtell Lipton Rosen & Katz, Macfarlanes LLP and Arthur Cox LLP; GW is represented by Cravath Swaine & Moore LLP and Slaughter and May....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!